SCHEMBL490685

SCHEMBL490685

O=C(O)C(Cc1cccc(O)c1O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.52
IAPP P10997 4/20 0.50
GABRA1 P14867 2/20 0.45
GABRB2 P47870 2/20 0.45
AKR1B1 P15121 1/20 0.45
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
ADAMTS4 O75173 1/20 0.42
ALDH1A1 P00352 1/20 0.42
EGFR P00533 1/20 0.42
LMNA P02545 1/20 0.42
FYN P06241 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
MMP8 P22894 1/20 0.42
CA6 P23280 1/20 0.42
CDK2 P24941 1/20 0.42
MMP12 P39900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6535663 0.85 SMN1; SMN2 (0.49) KMT2AIAPPGABRA1GABRB2AKR1B1
SCHEMBL490938 0.83 KMT2A (0.60) KMT2AAKR1B1CA1CA2ALDH1A1
SCHEMBL6700169 0.83 IAPP (0.50) IAPPGABRA1GABRB2AKR1B1CA1
SCHEMBL29540097 0.83 KDM4E (0.56) KMT2AIAPPALDH1A1EGFRLMNA
SCHEMBL157790 0.83 KDM4E (0.56) KMT2AIAPPALDH1A1EGFRLMNA
SCHEMBL1700767 0.83 KDM4E (0.56) KMT2AIAPPALDH1A1EGFRLMNA
SCHEMBL490445 0.82 KMT2A (0.44) KMT2AALDH1A1LMNAHSD17B10TDP1
Catechol SCHEMBL28214736 0.80 SLC7A5 (0.53) KMT2AIAPPAKR1B1ALDH1A1EGFR
SCHEMBL490722 0.79 CA12 (0.50) IAPPGABRA1GABRB2CA1CA2
SCHEMBL15117484 0.79 IAPP (0.46) KMT2AIAPPGABRA1GABRB2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-101163659-B Antioxidants MERCK PATENT GMBH 2012-09-05 CN disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
CN-101163659-A Antioxidants MERCK PATENT GMBH (DE) 2008-04-16 CN disclosed
EP-1871339-A1 UV PROTECTION Merck Patent GmbH (DE) 2008-01-02 EP disclosed
EP-1871735-A1 ANTIOXIDANTS Merck Patent GmbH (DE) 2008-01-02 EP disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
WO-2006111233-A1 ANTIOXIDANTS MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
EP-0517103-B1 Piperidine derivatives, a process for the preparation thereof and the use thereof 3V SIGMA SPA (IT) 1995-03-01 EP disclosed
US-4221701-A ESTERS OF TETRAMETHYLPIPERIDINOL WITH HYDROXYBENZYLMALONIC ACID CIBA-GEIGY CORPORATION (US) 1980-09-09 US disclosed
US-3993655-A ESTERS OF TETRAMETHYLPIPERIDINOLS CIBA-GEIGY CORPORATION (US) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT KMT2A 4023/4885IAPP 1118/4885GABRA1 3744/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 KMT2A 1522/4885IAPP 4855/4885GABRA1 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.